- Pain Experts to Discuss Developments in Kappa Opioid Receptor Agonists and the Future of Pain Management
- Company to Present Positive Data From Phase 2 Acute Pain and Human Abuse Liability Trials of CR845 in Poster Sessions
SHELTON, Conn., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will sponsor a symposium titled "Kappa Opioid Receptor Agonists (KORAs) – Moving Beyond Mu" at PAINWeek, to be held at the Cosmopolitan of Las Vegas. Preeminent pain experts will discuss the latest developments in analgesia, including efficacy, safety, and abuse potential results from Cara's Phase 2 acute pain and human abuse liability studies of CR845, the Company's first-in-class peripherally-selective kappa opioid agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.
The symposium details are as follows:
|Date: Friday, September 11, 2015|
|Time: 12:15-1:30 p.m. PT|
|Location: Castellana Ballroom, Level 3, the Cosmopolitan of Las Vegas|
- Joseph Pergolizzi, M.D., Adjunct Associate Professor, Department of Pharmacology, Temple University; Senior Partner, Naples Anesthesia and Pain Associates
- Gregory Holmquist, Pharm.D., CPE, Pain and Palliative Care Specialist, Palliative Care Strategies
- Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics; Assistant Professor, Department of Anesthesiology & Critical Care Medicine, Johns Hopkins University School of Medicine
In addition, the following scientific posters will be on display in Gracia 7 on the 3rd level of the Cosmopolitan of Las Vegas from 9:00 a.m. PT on Wednesday, September 9 through 5:00 p.m. PT on Friday, September 11:
- Poster #126: "Assessment of the low abuse potential of CR845, a kappa-opioid agonist"
- Poster #127: "CR845, a peripheral kappa opioid, provides better pain relief with less nausea and vomiting than placebo in patients after bunionectomy"
- Poster #128: "Analgesic efficacy of the peripheral kappa-opioid agonist CR845 in laparoscopic hysterectomy"
A poster reception will also be held Thursday, September 10 from 7:00-9:00 p.m. PT.
For more information on PAINWeek, visit: http://www.painweek.org/.
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was found to be safe and well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara expects to initiate its Phase 3 Program of I.V. CR845 for acute pain with a first adaptive pivotal trial in laparoscopic abdominal surgery in 3Q'15.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate to severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.